Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | GFER | P55789 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9598092 | 0.82 | RAPGEF4 (0.49) | RAPGEF4ESR1GAAPKMKDM4E | |
| SCHEMBL9599177 | 0.81 | RAPGEF4 (0.41) | RAPGEF4ESR1GAAPKMKDM4E | |
| SCHEMBL9260775 | 0.81 | RAPGEF4 (0.44) | RAPGEF4ESR1SMN1; SMN2GAAMAPT | |
| SCHEMBL9598706 | 0.79 | RAPGEF4 (0.39) | RAPGEF4ESR1GAAPKMHSD11B1 | |
| SCHEMBL4157574 | 0.79 | ENPP2 (0.39) | SMN1; SMN2GAAMAPTENPP2ALDH1A1 | |
| SCHEMBL4171578 | 0.78 | HRH3 (0.37) | SMN1; SMN2TP53PKMKDM4ENPC1 | |
| SCHEMBL7266691 | 0.78 | RAPGEF4 (0.38) | RAPGEF4ESR1SMN1; SMN2GAAMAPT | |
| SCHEMBL9599556 | 0.77 | KDM4E (0.42) | RAPGEF4ESR1SMN1; SMN2GAAMAPT | |
| SCHEMBL8940978 | 0.77 | HRH3 (0.37) | SMN1; SMN2TP53PKMKDM4ENPC1 | |
| SCHEMBL9599595 | 0.77 | RAPGEF4 (0.38) | RAPGEF4ESR1GAAPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0235111-B1 | INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1991-04-10 | — | — | EP | claimed |
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | ROSKAMP RESEARCH LLC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1993548-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | Roskamp Research LLC (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103683-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | ROSKAMP RESEARCH LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| US-5739340-A | Indolizine derivatives with pharmaceutical activity | ELF SANOFI (FR) | 1998-04-14 | — | — | US | disclosed |
| US-5403933-A | Chemical intermediates for cardiotonic, hypotensive, antiarrhymia and bradycadial agents; cognition activators | ELF SANOFI (FR) | 1995-04-04 | — | — | US | disclosed |
| US-5182291-A | Angina pectoris, hypotensive, antiarrhythmia, cerebral vascular insufficiency | SANOFI (FR) | 1993-01-26 | — | — | US | disclosed |
| US-5147878-A | Hypotensive, antiarrhythmia agents | SANOFI (FR) | 1992-09-15 | — | — | US | disclosed |
| US-5039700-A | Cardiovascular disorders, antitumor agents | SANOFI (FR) | 1991-08-13 | — | — | US | disclosed |
| US-5017579-A | Use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure | SANOFI (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4957925-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS, TREATMENT OF ANGINA | SANOFI (FR) | 1990-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | PSEN1, PSEN2, APP | RAPGEF4 2380/4885ESR1 4337/4885SMN1; SMN2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.